1414386-05-2
1414386-05-2
Chemical Structure
Sonelokimab
Synonym(s): ALX 0761; M 1095
- CAS 番号: 1414386-05-2
- Formula:N/A
- Molecular Weight:(40.11 kDa)
SMILES: [Sonelokimab]
Biological Activity: Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis[1][2][3][4].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sonelokimab | 99.81% | Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Torres T, et al. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs. 2016 Jul;25(7):751-4. [Content Brief]
- [2]. Rossotti MA, et al. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022 Jul;289(14):4304-4327. [Content Brief]
- [3]. Gao W, et al. Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis. Front Immunol. 2023 May 25;14:1151977. [Content Brief]
- [4]. Vanheusden K, et al. Pre-clinical proof-of-concept of ALX-0761, a Nanobody® neutralizing both IL-17A and F in a cynomolgus monkey collagen induced arthritis model[C]//ARTHRITIS AND RHEUMATISM. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: Wiley-Blackwell, 2013, 65: S543-S543.
Keywords
